Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -9 of 9
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Supportive care, Treatment
Active
18 and over
Other
2006-00055-18
NCT00415103
Last Modified:
5/29/2008
 
First Published:
5/11/2007
2.
Phase III Randomized Study of Different Combinations of Granisetron Hydrochloride, Dexamethasone, Prochlorperazine, Aprepitant, and Palonosetron Hydrochloride in Preventing Delayed Nausea in Women Undergoing Chemotherapy for Chemotherapy-Naive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Active
18 and over
NCI
URCC-04-02
URCC 0402, URCC-U1105, U1105, NCT00475085
Last Modified:
5/27/2008
 
First Published:
10/30/2007
3.
Phase III Randomized Study of Palonosetron Hydrochloride and Dexamethasone With or Without Dronabinol in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy for Solid tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Active
18 and over
NCI
MDA-2006-0841
2006-0841, NCT00553059
4.
Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Supportive care, Treatment
Active
18 to 65
Other
2005-0506
NCT00412425
Last Modified:
8/21/2008
 
First Published:
9/23/2006
5.
Phase II Study of Aprepitant, Palonosetron Hydrochloride, and Dexamethasone in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving FOLFOX or FOLFIRI Chemotherapy for Metastatic Colorectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Active
18 and over
NCI
OHSU-SOL-06006-LM
OHSU-IRB-2302, NCT00381862
Last Modified:
6/9/2008
 
First Published:
3/6/2008
6.
Phase II Pilot Study of Palonosetron Hydrochloride, Aprepitant, and Low-Dose Dexamethasone in Preventing Nausea and Vomiting in Patients Undergoing High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma or Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Active
18 to 75
Other
KUMC-10862
10862, MGI-KUMC-10862, NCT00631930
7.
Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care
Approved-not yet active
18 and over
Other
00002273
NCT00636805
Last Modified:
4/29/2008
 
First Published:
6/16/2006
8.
Study of Dexamethasone in Combination With Either Ondansetron or Palonosetron Hydrochloride in Preventing Acute and Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Early-Stage Breast Cancer Undergoing Chemotherapy Comprising Doxorubicin Hydrochloride and Cyclophosphamide
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Supportive care, Treatment
Active
18 and over
NCI, Pharmaceutical / Industry
UWCC-UW-6140
UWCC-05-9579-H/D, FHCRC-6140, MGI-FHCRC-6140, NCT00343863
9.
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Supportive care, Treatment
Active
18 to 65
Other
2005-0664
NCT00410488
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute